Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2012 2
2014 1
2016 1
2018 4
2019 2
2020 3
2021 4
2022 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Results by year

Filters applied: . Clear all
Page 1
Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis.
Lebwohl MG, Stein Gold L, Strober B, Papp KA, Armstrong AW, Bagel J, Kircik L, Ehst B, Hong HC, Soung J, Fromowitz J, Guenthner S, Piscitelli SC, Rubenstein DS, Brown PM, Tallman AM, Bissonnette R. Lebwohl MG, et al. N Engl J Med. 2021 Dec 9;385(24):2219-2229. doi: 10.1056/NEJMoa2103629. N Engl J Med. 2021. PMID: 34879448 Clinical Trial.
BACKGROUND: Tapinarof cream is a topical aryl hydrocarbon receptor-modulating agent under investigation for the treatment of psoriasis. Tapinarof modulates the expression of interleukin-17 and the skin-barrier proteins filaggrin and loricrin. ...
BACKGROUND: Tapinarof cream is a topical aryl hydrocarbon receptor-modulating agent under investigation for the treatment of psoriasi …
Efficacy and patient-reported outcomes from a phase 2b, randomized clinical trial of tapinarof cream for the treatment of adolescents and adults with atopic dermatitis.
Paller AS, Stein Gold L, Soung J, Tallman AM, Rubenstein DS, Gooderham M. Paller AS, et al. J Am Acad Dermatol. 2021 Mar;84(3):632-638. doi: 10.1016/j.jaad.2020.05.135. Epub 2020 Jun 2. J Am Acad Dermatol. 2021. PMID: 32502588 Free article. Clinical Trial.
BACKGROUND: Tapinarof is a topical therapeutic aryl hydrocarbon receptor modulating agent under investigation for atopic dermatitis (AD) and psoriasis treatment. ...RESULTS: Overall, 191 of 247 randomized patients completed the study. Week 12 IGA responses were higher in t …
BACKGROUND: Tapinarof is a topical therapeutic aryl hydrocarbon receptor modulating agent under investigation for atopic dermatitis ( …
A phase 2b, randomized clinical trial of tapinarof cream for the treatment of plaque psoriasis: Secondary efficacy and patient-reported outcomes.
Stein Gold L, Bhatia N, Tallman AM, Rubenstein DS. Stein Gold L, et al. J Am Acad Dermatol. 2021 Mar;84(3):624-631. doi: 10.1016/j.jaad.2020.04.181. Epub 2020 May 21. J Am Acad Dermatol. 2021. PMID: 32446832 Free article. Clinical Trial.
BACKGROUND: Tapinarof cream is a topical therapeutic aryl hydrocarbon receptor modulating agent under investigation for treatment of psoriasis and atopic dermatitis. ...Tapinarof responses were apparent from week 2, with significant efficacy at week 8 maintained thr …
BACKGROUND: Tapinarof cream is a topical therapeutic aryl hydrocarbon receptor modulating agent under investigation for treatment of …
Dermal Safety of Tapinarof Cream 1%: Results From 4 Phase 1 Trials.
Jett J, McLaughlin M, Wilson T, Somerville M, DellaMaestra W, Rubenstein D, Piscitelli S. Jett J, et al. J Drugs Dermatol. 2022 Oct 1;21(10):1084-1090. doi: 10.36849/JDD.6627. J Drugs Dermatol. 2022. PMID: 36219046 Clinical Trial.
METHODS: We conducted 4 randomized, controlled, phase 1 trials of topical tapinarof cream 1% vs vehicle or other appropriate controls in healthy adults. ...There was no evidence of sensitization, photosensitization, or phototoxicity. Tapinarof was well tolerated and …
METHODS: We conducted 4 randomized, controlled, phase 1 trials of topical tapinarof cream 1% vs vehicle or other appropriate controls …
Tapinarof Cream 1% for Extensive Plaque Psoriasis: A Maximal Use Trial on Safety, Tolerability, and Pharmacokinetics.
Jett JE, McLaughlin M, Lee MS, Parish LC, DuBois J, Raoof TJ, Tabolt G, Wilson T, Somerville MC, DellaMaestra W, Piscitelli SC. Jett JE, et al. Am J Clin Dermatol. 2022 Jan;23(1):83-91. doi: 10.1007/s40257-021-00641-4. Epub 2021 Oct 28. Am J Clin Dermatol. 2022. PMID: 34713415 Free PMC article. Clinical Trial.
BACKGROUND: Tapinarof is a novel topical therapeutic aryl hydrocarbon receptor modulating agent in development for the treatment of psoriasis and atopic dermatitis. ...Common AEs were folliculitis, headache, back pain, and pruritus (none led to discontinuation). Tapinar …
BACKGROUND: Tapinarof is a novel topical therapeutic aryl hydrocarbon receptor modulating agent in development for the treatment of p …
Phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of plaque psoriasis.
Robbins K, Bissonnette R, Maeda-Chubachi T, Ye L, Peppers J, Gallagher K, Kraus JE. Robbins K, et al. J Am Acad Dermatol. 2019 Mar;80(3):714-721. doi: 10.1016/j.jaad.2018.10.037. Epub 2018 Oct 26. J Am Acad Dermatol. 2019. PMID: 30612986 Clinical Trial.
Treatment-emergent adverse events were more frequent in patients treated with tapinarof (85/152, 56%) than vehicle (19/75, 25%) and mild-to-moderate in intensity. ...CONCLUSIONS: Tapinarof cream is efficacious and well tolerated in adult patients with psoriasis....
Treatment-emergent adverse events were more frequent in patients treated with tapinarof (85/152, 56%) than vehicle (19/75, 25%) and m …
A phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of atopic dermatitis.
Peppers J, Paller AS, Maeda-Chubachi T, Wu S, Robbins K, Gallagher K, Kraus JE. Peppers J, et al. J Am Acad Dermatol. 2019 Jan;80(1):89-98.e3. doi: 10.1016/j.jaad.2018.06.047. Epub 2018 Jul 3. J Am Acad Dermatol. 2019. PMID: 30554600 Clinical Trial.
Treatment success was maintained for 4 weeks after the end of tapinarof treatment. The rate of treatment-emergent adverse events was higher with tapinarof (93 of 165 [56%]) than with vehicle (34 of 82 [41%]), and the events were mild to moderate in intensity. LIMITA …
Treatment success was maintained for 4 weeks after the end of tapinarof treatment. The rate of treatment-emergent adverse events was …
Systemic Pharmacokinetics, Safety, and Preliminary Efficacy of Topical AhR Agonist Tapinarof: Results of a Phase 1 Study.
Bissonnette R, Vasist LS, Bullman JN, Collingwood T, Chen G, Maeda-Chubachi T. Bissonnette R, et al. Clin Pharmacol Drug Dev. 2018 Jun;7(5):524-531. doi: 10.1002/cpdd.439. Epub 2018 Feb 1. Clin Pharmacol Drug Dev. 2018. PMID: 29389078 Clinical Trial.
Tapinarof cream is a novel topical nonsteroidal agent that represents a unique class of anti-inflammatory molecules targeting the aryl hydrocarbon receptor. ...Tapinarof was systemically absorbed, and measurable amounts were detected in both cohorts. ...
Tapinarof cream is a novel topical nonsteroidal agent that represents a unique class of anti-inflammatory molecules targeting the ary …
A double-blind, randomized, placebo- and positive-controlled phase III trial of 1% benvitimod cream in mild-to-moderate plaque psoriasis.
Cai L, Chen GH, Lu QJ, Zheng M, Li YZ, Chen J, Zheng J, Zhang FR, Yu JB, Yang S, Li FQ, Xiao SX, Sun QN, Xu JH, Gao XH, Fang H, Gao TW, Hao F, Liu QZ, Tu YT, Li RY, Wang BX, Deng DQ, Zheng QS, Liu HX, Zhang JZ. Cai L, et al. Chin Med J (Engl). 2020 Nov 9;133(24):2905-2909. doi: 10.1097/CM9.0000000000001221. Chin Med J (Engl). 2020. PMID: 33177393 Free PMC article. Clinical Trial.
15 results